Pure Global
NCT04940520

Alpha-bisabolol for Onychomycosis Treatment

Universidade do Vale do Sapucai·Phase 1·ClinicalTrials.gov·biologicalCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Onychomycosis
Drug/Device/Intervention
Drug recommended by the Brazilian Society of Dermatology
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Universidade do Vale do Sapucai
Location
Pouso Alegre, Brazil
Timeline & enrollment
Phase
Phase 1
Start date
Jun 01, 2020
End date
May 01, 2021
Enrollment
60 participants
Primary outcome

Injury area analysis

Summary

Clinical, interventional, longitudinal study with random sampling. 60 patients will be
 divided into three groups, group A: control group, drug recommended by the Brazilian Society
 of Dermatology, group B: alpha bisabolol-based product associated with low-level laser
 therapy, and group C: alpha bisabolol based product. The topical application will be
 performed twice a day, while the laser application and photographs of the lesions, every 15
 days. Areas of the lesions will be compared.

ICD-10 classifications
OnychogryphosisChromomycosis, unspecifiedOnycholysisActinomycosisBlastomycosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04940520
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04940520 through Pure Global AI's free database. This Phase 1 trial is sponsored by Universidade do Vale do Sapucai and is currently Completed. The study focuses on Onychomycosis. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.